Quel est le prix pour Fresh Tracks Therapeutics, Inc. (FRTX)

Le prix pour Fresh Tracks Therapeutics, Inc. (FRTX) est $0.94

Quelle est la capitalisation boursière pour Fresh Tracks Therapeutics, Inc. (FRTX)

La capitalisation boursière pour Fresh Tracks Therapeutics, Inc. (FRTX) est $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) Prix et Capitalisation Boursière

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

Prix pour FRTX	L’actif B	La capitalisation boursière de B	Résultats
$1,876,002 $2.73M	NVDA	$5.452T	+199,574,612.63%
$1,545,028 $2.73M	AAPL	$4.490T	+164,364,578.08%
$1,432,295 $2.73M	GOOG	$4.162T	+152,371,752.22%
$1,265,039 $2.73M	MSFT	$3.676T	+134,578,547.49%
$974,858 $2.73M	AMZN	$2.833T	+103,708,151.11%

Prix pour FRTX

L’actif B

La capitalisation boursière de B

Résultats

$1,876,002 $2.73M